Compare Allstate Corp (ALL) vs GSK plc (GSK) Price & Performance

Allstate (ALL) trades at $256.24, down 4.98% on the day, but remains near recent highs with strong technical support at $253. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, driven by improved underwriting and investment income. Revenue growth has accelerated from $51.4B in 2022 to $67.1B in 2025, with net income margin expanding to 19.19%. Analyst consensus is a Buy with a $266.47 price target, though sentiment is mixed on sustainability of peak profitability.

Outlook is positive given earnings momentum and attractive valuation (P/E 5.25), but risks include potential normalization of underwriting margins and macroeconomic sensitivity. The stock offers value with high ROE (49.11%) and consistent dividend payments, yet investors should weigh cyclical insurance pressures against fundamental strength.

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.